The study is a first step to see if the vaccine appears safe enough for larger tests needed to prove whether it will protect. Even if the research goes well, it is expected to take over a year before any vaccine could be widely available.
Last month, the first safety test in people of a different vaccine candidate began in Seattle. It was developed by the National Institutes of Health and Moderna Inc.
Inovio’s approach is what’s called a DNA vaccine, made using a section of the virus’ genetic code packaged inside a piece of synthetic DNA.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.